US panel backs Sanofi-Aventis's Multaq
This article was originally published in Scrip
Executive Summary
Sanofi-Aventis's anti-arrhythmic Multaq (dronedarone) should be approved for treating atrial fibrillation (AF), the USFDA's outside advisors said on March 18th. The cardiovascular-renal drugs advisory committee nevertheless favoured a narrow indication and said the label should not claim a mortality benefit.
You may also be interested in...
Puberty Blockers: FDA's Califf Asked If REMS, Boxed Warning Against Off-Label Use In The Works
FDA Commissioner Robert Califf tells House appropriations subcommittee chair the agency will 'consider any information that may be available' on off-label use of puberty blockers for gender dysphoria before making a regulatory decision.
ADHD Drugs: FDA Commissioner Blames Inappropriate Prescribing For Shortages
ADHD drug shortages may have resulted from industry reticence to fill DEA quotas, as well as a 'heavy element of professional responsibility' with off-label prescribing, Robert Califf told a House appropriations subcommittee.
Drug Shortages, Inspections In Focus At US FDA Appropriations Hearing
Commissioner Robert Califf discussed the agency’s request for $12.3m to address shortages and legislation to require that manufacturers provide more detailed information about increased demand and supply chain vulnerabilities.